NCT00006239已完成1 期
A Phase I, Dose-Finding Trial of Sodium Phenylbutrate (NSC 657802) in Combination With All Trans-retinoic Acid (ATRA, NSC 122758) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
PURPOSE: Phase I trial to study the effectiveness of combining phenylbutyrate and tretinoin in treating patients who have hematologic cancer.
详细描述
OBJECTIVES:
- Determine the safety and toxicity of phenylbutyrate and tretinoin in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.
- Determine the pharmacokinetic interaction of this regimen in these patients.
- Determine any potential therapeutic activity of this regimen in these patients.
OUTLINE: This is a dose escalation study of tretinoin.
Patients receive phenylbutyrate IV continuously on days 1-7 of weeks 1, 5, 7, 9, 11, 13, 15, 17, and 19. Patients also receive oral tretinoin three times daily on days 1-7 of weeks 3, 5, 7, 9, 11, 13, 15, 17, and 19. Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tretinoin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose limiting toxicities.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed myelodysplastic syndrome (MDS)
- •Refractory anemia
- •Primary refractory leukopenia or thrombocytopenia with morphologic features of MDS
- •Refractory anemia with excess blasts (RAEB)
- •Refractory anemia with ringed sideroblasts
- •RAEB in transformation
- •Must have excess blasts or be hematopoietically compromised, defined as one of the following:
- •RBC transfusion dependent
- •Granulocyte count less than 1,000/mm^3
- •Platelet count less than 50,000/mm^3 OR
- •Diagnosis of chronic myelomonocytic leukemia
- •Hematopoietically compromised (as defined above) OR
- •Excess blasts OR
- •Evaluable disease related symptomatology (organomegaly or leukemia cutis) OR
- •Diagnosis of acute myeloid leukemia
- •WBC less than 20,000/mm^3 and stable for at least 2 weeks
- •Unlikely to require cytotoxic therapy during study
- •No CNS or pulmonary leukostasis or CNS leukemia
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Zubrod 0-2
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •See Disease Characteristics
- •Hemoglobin at least 8 g/dL (transfusion allowed)
- •No disseminated intravascular coagulation
- •Bilirubin less than 2.0 mg/dL (unless due to hemolysis or Gilbert's syndrome)
- •Creatinine less than 2.0 mg/dL
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception for 2 weeks prior, during, and for 3 months after study
- •No active infection
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •See Disease Characteristics
- •At least 3 weeks since prior biologic therapy, including hematopoietic growth factors, and recovered
- •Chemotherapy:
- •See Disease Characteristics
- •At least 3 weeks (1 month for MDS patients) since prior chemotherapy and recovered
- •Endocrine therapy:
- •Not specified
- •Radiotherapy:
- •At least 3 weeks since prior radiotherapy and recovered
- •Not specified
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesProstate CancerLung CancerLymphomaLeukemiaNCT00006019Memorial Sloan Kettering Cancer Center
已完成
2 期
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaLeukemiaNCT00006240National Heart, Lung, and Blood Institute (NHLBI)
已完成
1 期
Pyroxamide in Treating Patients With Advanced CancerChronic Myeloproliferative DisordersMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesPrecancerous ConditionSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaLeukemiaNCT00042900Memorial Sloan Kettering Cancer Center
已完成
1 期
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyMultiple Myeloma and Plasma Cell NeoplasmSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol SpecificProstate CancerLymphomaLeukemiaNCT00005634Memorial Sloan Kettering Cancer Center
已完成
1 期
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic CancerEndometrial CancerFallopian Tube CancerOvarian CancerCervical CancerSarcomaNCT00032162AGO Study Group63